BHVN
Biohaven Ltd.
$9.86
+1.23%
2026-05-08
About Biohaven Ltd.
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors. In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.
Key Fundamentals
Forward P/E
-4.87
EPS (TTM)
$-5.57
ROE
-333.0%
Profit Margin
0.0%
Debt/Equity
220.99
Price/Book
11.23
Beta
3.31
Market Cap
$1.45B
Avg Volume (10D)
1.8M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$12.10
60D Low
$8.03
Avg Volume
2.0M
Latest Close
$9.86
Get breakout alerts for BHVN
Sign up for Breakout Scanner to receive daily notifications when BHVN triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Biohaven Ltd. (BHVN) is listed on the New York Stock Exchange (NYSE). Breakout Scanner monitors BHVN daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. BHVN operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.